Pre-malignant Drivers Combined with Target-drug Validation in Mesothelioma
PREDICT-Meso is an International Network of researchers from across the UK and worldwide interested in the study of Mesothelioma, an incurable cancer most commonly affecting the lining of the lungs and caused by exposure to asbestos fibres.
Mesothelioma is preceded by decades of pleural inflammation providing a window of opportunity for precision prediction and early treatment that the Network wishes to explore. Together the teams hope to better understand how mesothelioma develops from its early stages and translate this into more effective diagnosis and treatment for patients.
PREDICT-Meso is funded for £5million across 6 years by the Accelerator Awards. The Accelerator Awards are funded through a partnership between Cancer Research UK (CRUK), Fondazione AIRC (AIRC) and Fundación Científica de la Asociacion Española Contra el Cáncer (FC AECC) and seeks to maximise impact through shared priorities.
The PREDICT-Meso project is comprised of expert mesothelioma researchers from across Europe and is arranged into 5 work-packages designed to collect and utilise human tissues and data to design new therapies and early detection tests for Mesothelioma.
The Accelerator Award enables team science across Europe. It supports the creation of high-quality tools and resources that will unlock new research into unanswered questions about cancer.
Mesothelioma is an incurable cancer that develops many decades after inhalation of asbestos dust and fibres.
Mesothelioma is an incurable cancer that develops many decades after inhalation of asbestos dust and fibres. Few treatment options exist, and unfortunately most patients die within a year. A long latent period after asbestos exposure is common (30-50 years), characterized by chronic asbestos-driven pleural inflammation, but the factors that promote or permit mesothelioma evolution are poorly understood.
Critically, mesothelioma may be preceded by a benign manifestation of pleural inflammation known as Asbestos Associated Pleural Inflammation. This presents with a fluid collection in the chest, which requires drainage and biopsies to exclude mesothelioma.
With the UK incidence of mesothelioma currently the highest in the world, global death rates rising rapidly (currently 43,000/year) and an epidemic predicted in the BRIC countries (Brazil, Russia, India, China) there is an urgent need to accelerate research, particularly in relation to target identification and drug development.
Accurate risk prediction and response tools are also required to deliver effective early intervention trials.
For more information on mesothelioma please check out Mesothelioma UK